Business
Taiwan's Bora Pharma adds MacroGenics' GMP manufacturing for USD 127.5m
Taiwan-based Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) has agreed to acquire the GMP manufacturing operations of MacroGenics (Nasdaq: MGNX) for USD...
In vivo CAR-T funding continues to flow as Create Medicines raises USD 122m in Series B
CREATE Medicines raises USD 122 million Series B to advance in vivo CAR pipeline
Degron Therapeutics closes USD 40 million Series A extension for molecular glue degraders
A targeted protein degradation company with a clinical-stage molecular glue degrader program has secured additional capital to fund its lead oncology asset...
AstraZeneca enters three-year license agreement with Owkin for K Pro agentic AI platform
AstraZeneca (LSE/NYSE: AZN) has entered a three-year license agreement with Owkin, a privately held AI company founded in 2016 and headquartered across New...
METiS TechBio raises USD 269m via Hong Kong listing, attracting USD 148m cornerstone commitments
I need to flag a conflict between the system instructions and the user prompt before producing the article.
Aurigene secures non-exclusive CRISPR/Cas9 license from ERS Genomics for drug discovery
Aurigene Pharmaceutical Services, a contract research and manufacturing subsidiary of Dr. Reddy's Laboratories (NYSE: RDY), has secured a non-exclusive...
Fosun Pharma secures USD 60m option on AriBio's PDE5 inhibitor for Alzheimer's disease
Fosun Pharma's subsidiary has committed USD 60 million upfront to secure an exclusive option over the global rights to AR1001, a Phase III oral PDE5...
Daiichi Sankyo's three imminent regulatory decisions and next-generation platforms reshape growth trajectory
Daiichi Sankyo's Q4 2026 earnings call on May 11, 2026 revealed three converging regulatory decisions — for Enhertu (trastuzumab deruxtecan), Datroway...
PharmAla Biotech forms Restora Neurosciences SPV with Aluvaris for MDXX clinical development
PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF), Toronto, has structured a special purpose vehicle to advance APA-01, a patented pre-IND MDXX-class small...
Whitehawk Therapeutics raises USD 87.5m in private placement to extend ADC runway through 2028
A clinical-stage antibody drug conjugate company is extending its cash runway into the second half of 2028 through a USD 87.5 million private placement,...
Collegium acquires Azstarys from Corium Therapeutics for USD 650m plus contingent payments
Collegium Pharmaceutical (Nasdaq: COLL), headquartered in Stoughton, Massachusetts, has completed the acquisition of Azstarys (serdexmethylphenidate and...
Rigel acquires Veppanu from Arvinas and Pfizer for USD 85m upfront
Rigel Pharmaceuticals (Nasdaq: RIGL) is acquiring exclusive global rights to Veppanu (vepdegestrant), the first US FDA-approved oral PROTAC, in a deal that...
Cerevance closes USD 20 million Series C as Phase III Parkinson's trial reaches full enrollment
Cerevance's Phase III Parkinson's trial reaches full enrollment as USD 20 million Series C extends runway
Deep Mind spin out Isomorphic Labs secures USD 2.1b Series B to scale AI drug design engine
A USD 2.1 billion Series B round positions London-based Isomorphic Labs as one of the most heavily capitalized AI-native drug design companies in the world,...
20/20 BioLabs licenses PSA velocity algorithm from University of South Carolina for cancer detection
20/20 BioLabs licenses a PSA velocity algorithm from the University of South Carolina, adding a longitudinal biomarker analysis tool to its multi-cancer...
The AllSci Brief
Systematic R&D and deal news. Daily.